Document is current

Article History

Received: 18 March 2024

Accepted: 30 April 2024

First Online: 29 May 2024

Declarations

:

: This study has been approved by the French Health Data Hub. This study is a non-interventional study not involving the human being, leveraging only anonymized structured data, which according to applicable legal requirements do not contain data subject to privacy laws. Hence, obtaining informed consent from patients was not required.

: As this study involved anonymized structured data, which according to applicable legal requirements do not contain data subject to privacy laws, obtaining consent to publish from patients was not required.

: K.M. reports consulting fees from Novo Nordisk; honoraria for lectures, presentations, or speaker bureaus from Novo Nordisk, Astra Zeneca, Boehringer-Ingelheim, Eli Lilly, Sanofi, Lifescan, Abbott, and Bayer; and participation to Advisory Board from Novo Nordisk, Sanofi and Amarin. L.F reports consultant activities for Bayer, BMS/Pfizer, Boehringer Ingelheim, Medtronic, Novartis, Novo Nordisk and XO, and speaker activities for AstraZeneca, Bayer, BMS/Pfizer, Boehringer Ingelheim, Boston Scientific, Medtronic, Novartis, Novo Nordisk and Zoll. NQ, AK, RK and KK are full-time employees at Certara, a contract research organization which received consulting fees to independently conduct this study. TB is a former employee at Certara. HR, CM, LV, and SL are all full-time employees of Novo Nordisk. I.S reports consultant activities for Bayer, BMS/Pfizer, Boehringer Ingelheim, Medtronic, Novartis, Novo Nordisk, Bioprojet, Astra-Zeneca, Alexion and speaker activities for AstraZeneca, Bayer, BMS/Pfizer, Boehringer Ingelheim, Medtronic, Novartis, Novo Nordisk.